Why Telehealth Access Exists
GLP-1 therapy requires a prescription from a licensed medical provider. That has always been true. What telehealth changed is the ability to complete the clinical consultation, intake review, and prescription process without requiring an in-person visit — making access significantly more practical for patients who do not have a physician relationship, cannot afford a specialist visit, or live in areas with limited access to metabolic medicine specialists.
Telehealth prescribing for semaglutide is legal, clinically legitimate, and widely practiced. The FDA explicitly permits telehealth consultations for prescription medications. The clinical quality of that consultation — not the modality — is what determines whether the process is medically sound.
What a Legitimate Intake Actually Includes
Health history review. A provider issuing a GLP-1 prescription needs to know your medical history — specifically, whether you have any contraindications for GLP-1 therapy. This includes personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, a history of pancreatitis, and any medications that interact with GLP-1 agonists. An intake that does not ask about these things is not conducting a real clinical review.
Weight and BMI assessment. GLP-1 therapy for weight management is indicated for patients with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity (such as hypertension, dyslipidemia, or sleep apnea). A provider issuing a prescription without assessing candidacy against these criteria is prescribing outside clinical guidelines.
Identity verification. Your health record needs to be associated with your actual identity. A legitimate platform includes identity verification as part of the intake process.
Actual physician review. Not an algorithm. Not a rubber stamp. A licensed physician or nurse practitioner reviews your intake and makes a clinical determination about candidacy. If a platform offers instant or near-instant approval with no evident review time, that is a signal worth paying attention to.
"The telehealth intake is not a formality before you get the drug you already decided you want. It is the clinical safeguard that determines whether the drug is appropriate for you. A provider who treats it as a formality is not providing clinical care."
Red Flags: What Signals a Low-Quality Provider
Instant approval. If a platform approves your prescription in minutes without any evident clinical review window, the review did not happen in any meaningful sense.
No intake questions about contraindications. If an intake form does not ask about thyroid cancer history, pancreatitis, or current medications, the provider is not screening for contraindications.
No information about pharmacy source. If a provider cannot tell you which 503B facility produces your medication, or deflects when asked, that is a meaningful red flag about sourcing quality.
No ongoing clinical relationship. A legitimate protocol includes follow-up. Someone should be checking in on your titration, side effect experience, and progress. A provider who issues a prescription and disappears is not providing clinical oversight — they are processing transactions.
Real clinical review. Licensed providers.
503B sourced. All 50 states.
What Happens After Approval
Once a provider approves your prescription, the medication is compounded to order and shipped directly to your address. Delivery times vary by pharmacy, but most 503B partners ship within a few business days of prescription authorization. Medications arrive in proper temperature-controlled packaging — semaglutide requires refrigeration.
From there, your provider should outline a clear titration schedule and be accessible for questions as you begin the protocol. Side effects, dosing questions, and clinical check-ins are part of what you are paying for. If those things are not available, you are not getting clinical care — you are getting a product.